Humacyte

Humacyte Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Humacyte (HUMA) as of Nov 21, 2026 is 257.25 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 65.99 % — a change of 289.85% (higher).

Cash Conversion

257.25 %

YoY

289.85%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Humacyte is 2025 257.25 % . Cash Conversion Rate (OCF/Net Income) of Humacyte was 2024 65.99 % . It decreases by 289.85% higher compared to the previous year.

The Humacyte Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
84.04 USD
Jan 1, 2020
83.53 USD
Jan 1, 2021
306.64 USD
Jan 1, 2022
594.48 USD
Jan 1, 2023
66.17 USD
Jan 1, 2024
65.99 USD
Jan 1, 2025
257.25 USD
The Humacyte Cash Conversion history
YEARCash ConversionYoY
257.25 %+289.85%
65.99 %-0.28%
66.17 %-88.87%
594.48 %+93.87%
306.64 %+267.10%
83.53 %-0.60%
84.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Cash Conversion Rate (OCF/Net Income) of Humacyte is 257.25 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Humacyte changed from 65.99 % to 257.25 %, representing a 289.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Humacyte since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Humacyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humacyte

All Key Metrics — Humacyte